UNSPSC 51422506: Cicortonide

This classification denotes a therapeutic glucocorticoid with the molecular formula C29H37ClFNO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UL947A614K, chemically known as 3-(2-chloroethoxy)-9-fluoro-11beta, 16alpha,17,21-tetrahydroxy-20-oxopregna-3,5-diene-6-carbonitrile, cyclic 16,17-acetal with acetone, 21-acetate. but generally known as cicortonide, which bears US NIH Compound Identifier 193972.

UNSPSC 51422506 Cicortonide is a Commodity code tracking pharmaceutical procurement by state and local health agencies. The recent solicitations under this code show state and local governments buying naloxone products and drug deactivation systems for community health and public safety initiatives, as well as exploring direct-to-manufacturer pharmacy benefit contracting models that may affect pharmaceutical procurement pathways. The issuing bodies include county health departments and state health and human services agencies managing pharmacy benefit programs, substance-abuse response capabilities, and prescription fulfillment for employee and retiree populations.

Seminole County, Florida, posted an IFB on June 30, 2026 (Solicitation IFB60459723LAS, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford; the procurement required electronic bid submission, drug-free workplace certification, E-Verify compliance, and included a three-month probationary period with potential FEMA funding. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 (HHS0017013) to gather vendor capabilities on direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and group purchasing organizations, seeking vendor experience with negotiated net pricing models and outcomes-based agreements for self-insured employer and government health plans. Recent activity concentrates in Florida and Texas, with scope spanning both emergency response pharmaceuticals (naloxone) and systemic pharmacy benefit restructuring at the state level.